AbbVie’s Hepatitis C Combo Therapy Shows Promise in Japanese Trial

Hepatitis C
January 17, 2017
Mammograms lead to unneeded treatment for some breast cancers
January 18, 2017
Show all

AbbVie’s Hepatitis C Combo Therapy Shows Promise in Japanese Trial

A one-pill combination medicationfor chronic hepatitis C had a successful initial trial in patients.

AbbVie’s new hepatitis C treatment candidate, a one tablet combination of the investigational drugs glecaprevir and pibrentasvir, harnessed the infection in all patients who completed a Japanese study.

The treatment, which worked after eight weeks, is developed to speed up the time to clear the virus from the body, and is effective against all major virus genotypes. Patients with a sustained virologic response at 12 weeks after treatment (SVR12) were considered cured of hepatitis C.

The study was part of a Phase 3 open-label clinical trial (NCT02707952; CERTAIN-1), comparing glecaprevir/pibrentasvir to treatment with Technivie, a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. The study included 158 patients with genotype 1 chronic hepatitis C but without cirrhosis. Among the 106 patients receiving the glecaprevir/pibrentasvir combo were 23 patients with the resistance-associated Y93H virus variant.

Patients who received glecaprevir/pibrentasvir were treated for eight weeks, while those on Technivie received 12 weeks of treatment. One patient in the glecaprevir/pibrentasvir group was lost to follow-up, but the remaining 105 patients, constituting 99 percent of the group, had a sustained virologic response at 12 weeks.

Read full article: AbbVie’s Hepatitis C Combo Therapy Shows Promise in Japanese Trial

Read Full Article: AbbVie’s Hepatitis C Combo Therapy Shows Promise in Japanese Trial

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.